DE60116359D1 - Kahalalid f formulierung - Google Patents

Kahalalid f formulierung

Info

Publication number
DE60116359D1
DE60116359D1 DE60116359T DE60116359T DE60116359D1 DE 60116359 D1 DE60116359 D1 DE 60116359D1 DE 60116359 T DE60116359 T DE 60116359T DE 60116359 T DE60116359 T DE 60116359T DE 60116359 D1 DE60116359 D1 DE 60116359D1
Authority
DE
Germany
Prior art keywords
kahalalide
formulation
formulations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60116359T
Other languages
English (en)
Other versions
DE60116359T2 (de
Inventor
Glynn Thomas Faircloth
Bastian Nuyen
Steve Weitman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmamar SA
Original Assignee
Pharmamar SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmamar SA filed Critical Pharmamar SA
Application granted granted Critical
Publication of DE60116359D1 publication Critical patent/DE60116359D1/de
Publication of DE60116359T2 publication Critical patent/DE60116359T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Liquid Crystal Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Carbon And Carbon Compounds (AREA)
  • Superconductors And Manufacturing Methods Therefor (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
  • Diaphragms For Electromechanical Transducers (AREA)
DE60116359T 2000-10-31 2001-10-31 Kahalalid f formulierung Expired - Lifetime DE60116359T2 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US24447100P 2000-10-31 2000-10-31
US244471P 2000-10-31
US24622900P 2000-11-06 2000-11-06
US246229P 2000-11-06
US34844901P 2001-10-19 2001-10-19
US348449P 2001-10-19
PCT/GB2001/004821 WO2002036145A2 (en) 2000-10-31 2001-10-31 Kahalalide f formulation

Publications (2)

Publication Number Publication Date
DE60116359D1 true DE60116359D1 (de) 2006-02-02
DE60116359T2 DE60116359T2 (de) 2006-09-28

Family

ID=27399760

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60116359T Expired - Lifetime DE60116359T2 (de) 2000-10-31 2001-10-31 Kahalalid f formulierung

Country Status (22)

Country Link
US (1) US7473681B2 (de)
EP (1) EP1330258B1 (de)
JP (2) JP2004512370A (de)
KR (1) KR100834138B1 (de)
CN (1) CN1568192A (de)
AT (1) ATE314084T1 (de)
AU (2) AU2002210749B2 (de)
BR (1) BR0114912A (de)
CA (1) CA2425627A1 (de)
CY (1) CY1105009T1 (de)
CZ (1) CZ20031211A3 (de)
DE (1) DE60116359T2 (de)
DK (1) DK1330258T3 (de)
ES (1) ES2256305T3 (de)
HK (1) HK1054192B (de)
HU (1) HUP0600031A3 (de)
IL (2) IL155297A0 (de)
MX (1) MXPA03003704A (de)
NO (1) NO331082B1 (de)
NZ (1) NZ525243A (de)
SK (1) SK286421B6 (de)
WO (1) WO2002036145A2 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0002952D0 (en) * 2000-02-09 2000-03-29 Pharma Mar Sa Process for producing kahalalide F compounds
US20050054555A1 (en) * 2001-10-19 2005-03-10 Jose Jimeno Kahalalide compounds for use in cancer therapy
WO2003033012A1 (en) * 2001-10-19 2003-04-24 Pharma Mar, S.A. Kahalalide compounds for use in cancer therapy
GB0304367D0 (en) * 2003-02-26 2003-04-02 Pharma Mar Sau Methods for treating psoriasis
JP4430009B2 (ja) * 2002-10-18 2010-03-10 ファーマ・マール・エス・アー・ウー 新規な抗腫瘍化合物
PT1572726E (pt) * 2002-10-18 2011-02-14 Pharma Mar Sau Composto kahalalide f 4-metil-hexanóico
US7507708B2 (en) * 2003-02-26 2009-03-24 Pharma Mar, S.A.U. Antitumoral compounds
DE10329847A1 (de) * 2003-07-02 2005-01-20 Toximed Gmbh Pharmazeutischer Wirkstoff gegen Prostatakarzinome
GB0321066D0 (en) 2003-09-09 2003-10-08 Pharma Mar Sau New antitumoral compounds
GB0408958D0 (en) * 2004-04-22 2004-05-26 Pharma Mar Sa Convergent synthesis for kahalalide compounds
BRPI0518250A2 (pt) * 2004-10-26 2008-11-11 Pharma Mar Sa tratamentos anticÂncer
NZ554761A (en) * 2004-10-29 2010-01-29 Pharma Mar Sa Formulations comprising ecteinascidin and a disaccharide
GB0522082D0 (en) * 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
NZ584695A (en) * 2007-10-19 2011-06-30 Pharma Mar Sa Improved antitumoral treatments using PM02734 and an EGFR tyrosine kinase inhibitor (erlotinib)
EP2252315A1 (de) * 2008-01-30 2010-11-24 Pharma Mar, S.A. Verbesserte antitumorale behandlungen
CA2717117A1 (en) * 2008-03-07 2009-09-11 Pharma Mar, S.A. Improved antitumoral treatments
WO2009135939A2 (en) * 2008-05-09 2009-11-12 Pharma Mar, S.A. Depsipeptide for use in cancer therapy
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5037644A (en) * 1986-10-27 1991-08-06 Cetus Corporation Pharmaceutical compositions of recombinant interleukin-2 and formulation processes
JP2799483B2 (ja) 1988-03-09 1998-09-17 大塚製薬株式会社 インターロイキン−１β組成物の安定化方法
GB8819607D0 (en) 1988-08-17 1988-09-21 Wellcome Found Novel combination
IE64738B1 (en) 1990-03-20 1995-09-06 Akzo Nv Stabilized gonadotropin containing preparations
JP2971680B2 (ja) 1991-10-02 1999-11-08 山之内製薬株式会社 組織プラスミノーゲン活性化因子含有組成物
JPH0597703A (ja) 1991-10-04 1993-04-20 Yamanouchi Pharmaceut Co Ltd 改変型組織プラスミノーゲン活性化因子含有組成物
US5550124A (en) 1991-12-10 1996-08-27 University Of Southern California Use of peripheral-type benzodiazpine sites for treatment of CNS trauma or disease
US5849704A (en) * 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
US6274551B1 (en) * 1994-02-03 2001-08-14 Pharmamar, S.A. Cytotoxic and antiviral compound
GB9302046D0 (en) * 1993-02-03 1993-03-24 Pharma Mar Sa Antiumoral compound-v
JP3927248B2 (ja) * 1995-07-11 2007-06-06 第一製薬株式会社 Ｈｇｆ凍結乾燥製剤
GB9601120D0 (en) 1996-01-19 1996-03-20 Sandoz Ltd Organic compounds
JPH1014581A (ja) 1996-07-08 1998-01-20 Morinaga Milk Ind Co Ltd ウサギ型マクロファージ・コロニー刺激因子及びこれをコードするｄｎａ断片
JP4025394B2 (ja) * 1996-09-06 2007-12-19 財団法人化学及血清療法研究所 組織プラスミノーゲン活性化因子医薬組成物
US6139838A (en) 1996-09-06 2000-10-31 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Tissue plasminogen activator medicinal composition
GB9803448D0 (en) 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
GB9807639D0 (en) 1998-04-14 1998-06-10 Kennedy Rheumatology Inst Anti-inflammatory agents
IL142120A0 (en) 1998-09-23 2002-03-10 Neuroimmunophilins for selective neuronal radioprotection
GB0002952D0 (en) 2000-02-09 2000-03-29 Pharma Mar Sa Process for producing kahalalide F compounds
US20050054555A1 (en) 2001-10-19 2005-03-10 Jose Jimeno Kahalalide compounds for use in cancer therapy

Also Published As

Publication number Publication date
HK1054192A1 (en) 2003-11-21
NO331082B1 (no) 2011-10-03
CY1105009T1 (el) 2010-03-03
JP2010047601A (ja) 2010-03-04
PL360848A1 (en) 2004-09-20
KR20030044005A (ko) 2003-06-02
KR100834138B1 (ko) 2008-06-02
DE60116359T2 (de) 2006-09-28
HUP0600031A2 (en) 2006-05-29
US20040067895A1 (en) 2004-04-08
SK286421B6 (sk) 2008-09-05
HK1054192B (zh) 2006-09-08
DK1330258T3 (da) 2006-05-22
CN1568192A (zh) 2005-01-19
CZ20031211A3 (cs) 2003-09-17
HUP0600031A3 (en) 2012-02-28
CA2425627A1 (en) 2002-05-10
MXPA03003704A (es) 2004-05-04
ATE314084T1 (de) 2006-01-15
ES2256305T3 (es) 2006-07-16
SK5022003A3 (en) 2003-12-02
IL155297A (en) 2010-05-31
US7473681B2 (en) 2009-01-06
JP2004512370A (ja) 2004-04-22
WO2002036145A8 (en) 2003-10-23
AU1074902A (en) 2002-05-15
EP1330258A2 (de) 2003-07-30
WO2002036145A3 (en) 2002-10-17
NO20031860D0 (no) 2003-04-25
EP1330258B1 (de) 2005-12-28
IL155297A0 (en) 2003-11-23
AU2002210749B2 (en) 2006-12-21
NZ525243A (en) 2005-01-28
BR0114912A (pt) 2003-10-14
NO20031860L (no) 2003-06-30
WO2002036145A2 (en) 2002-05-10

Similar Documents

Publication Publication Date Title
DE60116359D1 (de) Kahalalid f formulierung
UY34152A (es) ?oxazolidinonas substituidas y su uso?.
NO20004540L (no) Sammensetninger av peptider, formuleringer og anvendelse derav
TR200202194T2 (tr) Poliglütamik asit-kamptotesin birleşikleri ve hazırlama yöntemleri
MXPA03005769A (es) Politrimetilen eter ester amida y uso de la misma.
DK0760848T3 (da) Lactobacillusstammer af menneskelig oprindelse, deres sammensætninger og anvendelse deraf
DE60010098D1 (de) 28-epirapaloge
HN2001000217A (es) Nuevos tiadiazoles y oxadiazoles y su uso como inhibidores de fosfodiesterasa - 7
HK1071152A1 (en) Silicone rubber formulations and the use thereof
ES2180319T3 (es) Utilizacion de derivados de metilenbisoxazolidina y composiciones de los mismos.
BR0110577A (pt) Decorina transgenicamente produzida
DE50310323D1 (de) Wässrige polyurethanzubereitungen
ITMI20031714A1 (it) Formazioni ad azione antitumorale.
MXPA03011128A (es) Composicion de sabor y fragancia.
AR030853A1 (es) Composicion plaguicida
DE60114039D1 (de) Kautschukzusammensetzungen und vulkanisate einschliesslich verzweigter kammpolymere
AU144678S (en) Bottle
BR0110902A (pt) Inibidores de mmp-9/mmp-2
BR0115856B1 (pt) composição betuminosa, e, uso da composição.
NO20005548D0 (no) Mykobakterieinhibitorer
BR0316544A (pt) Compostos calcilìticos
PT1274426E (pt) Uso de tioamida-oxazolidinonas no tratamento da reabsorcao ossea e da osteoporose
DE60124148D1 (de) Kalzilytische verbindungen
ATE364619T1 (de) Tibolonformulierungen
AU2001297794A1 (en) Methods and compositions of human proteins and uses thereof.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition